1,026 Experimental treatments in acute stroke

Annals of Neurology - Tập 59 Số 3 - Trang 467-477 - 2006
Victoria O’Collins1, Robert M. Califf2, Geoffrey A. Donnan3, Laura L. Horky3, Bart H. van der Worp4, David W. Howells1
1Neuroscience Lab, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Australia
2School of Molecular and Clinical Medicine, University of Edinburgh, Edinburgh, United Kingdom
3National Stroke Research Institute, Heidelberg Heights, Australia
4Department of Neurology, University Medical Centre Utrecht, Utrecht, the Netherlands

Tóm tắt

AbstractObjectivePreclinical evaluation of neuroprotectants fostered high expectations of clinical efficacy. When not matched, the question arises whether experiments are poor indicators of clinical outcome or whether the best drugs were not taken forward to clinical trial. Therefore, we endeavored to contrast experimental efficacy and scope of testing of drugs used clinically and those tested only experimentally.MethodsWe identified neuroprotectants and reports of experimental efficacy via a systematic search. Controlled in vivo and in vitro experiments using functional or histological end points were selected for analysis. Relationships between outcome, drug mechanism, scope of testing, and clinical trial status were assessed statistically.ResultsThere was no evidence that drugs used clinically (114 drugs) were more effective experimentally than those tested only in animal models (912 drugs), for example, improvement in focal models averaged 31.3 ± 16.7% versus 24.4 ± 32.9%, p > 0.05, respectively. Scope of testing using Stroke Therapy Academic Industry Roundtable (STAIR) criteria was highly variable, and no relationship was found between mechanism and efficacy.InterpretationThe results question whether the most efficacious drugs are being selected for stroke clinical trials. This may partially explain the slow progress in developing treatments. Greater rigor in the conduct, reporting, and analysis of animal data will improve the transition of scientific advances from bench to bedside. Ann Neurol 2006

Từ khóa


Tài liệu tham khảo

10.1136/bmj.328.7438.514

10.1161/01.STR.0000025518.34157.51

10.1602/neurorx.1.1.36

10.1016/S0165-6147(03)00192-5

10.1161/str.33.1.306

10.2165/00023210-200115030-00001

10.1111/j.1365-2796.1995.tb01144.x

10.1161/01.STR.0000125719.25853.20

10.1038/sj.jcbfm.9600064

10.1007/s00415-005-0802-3

10.1161/01.STR.30.12.2752

10.1097/00004647-200007000-00001

10.1161/01.STR.30.7.1486

10.1152/physrev.1999.79.4.1431

10.1016/S0165-6147(97)01157-7

Cochrane Central Register of Controlled Trials (CENTRAL).2005.The Cochrane Collaboration John Wiley & Sons Ltd.

Stroke Center. Clinical trials directory. Online:http://www.strokecenter.org.2005.

Sharma SS, 2003, Emerging neuroprotective approaches in stroke treatment, Current Research & Information on Pharmaceutical Sciences, 4, 8

10.1602/neurorx.1.1.46

10.1161/01.CIR.100.25.2541

Huang R, 1999, [Effects of defibrinogenase on photochemically induced middle cerebral artery occlusion in stroke‐prone renovascular hypertensive rats], Zhonghua Yi Xue Za Zhi, 79, 711

10.1016/0014-2999(92)90037-5

10.1016/0197-0186(95)00117-4

10.1038/jcbfm.1994.121

AstraZeneca. First results from SAINT I trial show AstraZeneca's Cerovine (NXY‐059) demonstrates a reduction in disability in patients with acute ischemic stroke.http://www.astrazeneca.com/pressrelease/4979.aspx 2005.

10.1111/j.1600-079X.2004.00172.x

10.1097/00004647-199912000-00004

WHO. The World Health Report 2003. Online athttp://www.who.int/whr/2003/en/Facts_and_Figures‐en.pdf 2003.

Thông tin
Thông tin xuất bản

Annals of Neurology

Tập 59 Số 3

467-477

Thông tin tác giả